CLINICAL_TRIALS
trial_result
· 2016-05-13
Clinical Trial Update: A 24-52-week Study to Evaluate the Long-term Efficacy and Safety of Saredutant in Patients With Depression (MAGENTA) [Phase 3]
Summary
A completed Phase 3 study evaluating the long-term efficacy and safety of Saredutant in patients with major depressive disorder.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Sanofi | Conditions: Depressive Disorder | Phase 3 | Status: COMPLETED